Leiden, The Netherlands, November 9, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical results at the virtual 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), occurring November 9-14. The in vitro and in vivo data presented at SITC highlight the potential impact of the company’s lead vaccine candidate, DCP-001, on ovarian cancer treatment and post-remission therapy. The accepted abstract is listed below and is now available online on the SITC website.
Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH Annual Meeting and Exposition on December 5, 2020. The Interim data on both primary and secondary endpoints of the trial highlight the potential of the company’s lead vaccine candidate, DCP-001, to improve the treatment options for patients with Acute Myeloid Leukemia (AML) in the post-remission setting. The study continues to enroll patients at the higher of two vaccine doses tested and updated data will be shown at ASH.